SCHEMBL23817969

SCHEMBL23817969

CC(=O)N1CCOc2ccc(N(CCC#N)C(=O)CCl)cc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FNIP1 Q8TF40 1/20 0.67
▸ FEM1B Q9UK73 1/20 0.67
▸ ALDH1A1 P00352 7/20 0.54
▸ RAB9A P51151 3/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ HTT P42858 3/20 0.48
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ NOTUM Q6P988 1/20 0.44
▸ MAPT P10636 3/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ PDE3B Q13370 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23818490 0.91 FNIP1 (0.53) FNIP1FEM1BALDH1A1RAB9ASMN1; SMN2
SCHEMBL25455177 0.90 FNIP1 (0.53) FNIP1FEM1BALDH1A1RAB9ASMN1; SMN2
SCHEMBL23817966 0.88 FEM1B (0.61) FNIP1FEM1BALDH1A1RAB9ASMN1; SMN2
SCHEMBL23818481 0.84 FEM1B (0.55) FNIP1FEM1BALDH1A1RAB9ASMN1; SMN2
SCHEMBL23817837 0.84 FEM1B (0.54) FNIP1FEM1BALDH1A1RAB9ASMN1; SMN2
SCHEMBL25171623 0.83 FEM1B (0.68) FNIP1FEM1BALDH1A1RAB9ASMN1; SMN2
SCHEMBL23804991 0.81 FNIP1 (1.00) FNIP1FEM1BALDH1A1RAB9ASMN1; SMN2
SCHEMBL23804989 0.80 FEM1B (0.61) FNIP1FEM1BALDH1A1RAB9ASMN1; SMN2
SCHEMBL30132890 0.80 FEM1B (0.61) FNIP1FEM1BALDH1A1RAB9ASMN1; SMN2
SCHEMBL23818422 0.79 FEM1B (0.60) FNIP1FEM1BALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230148299-A1 FEM1B PROTEIN BINDING AGENTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-05-11 — — US disclosed
US-20230148299-A1 FEM1B PROTEIN BINDING AGENTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-05-11 — — US disclosed
WO-2021183431-A1 FEM1B PROTEIN BINDING AGENTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148299-A1 FEM1B PROTEIN BINDING AGENTS AND USES THEREOF FEM1B, GSKIP, FNIP1 FNIP1 3/4885FEM1B 1/4885ALDH1A1 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback